<DOC>
	<DOCNO>NCT00346437</DOCNO>
	<brief_summary>The purpose study determine whether single intracoronary infusion Ad5FGF-4 effective improving exercise capacity measure exercise treadmill test , angina functional class , patient symptom , quality life , cardiovascular outcome . Two dos study , 2.87 x 10 ( 8 ) 2.87 x 10 ( 9 ) viral particle , evaluate dose-response Ad5FGF-4 . Short-term long-term safety Ad5FGF-4 also evaluate .</brief_summary>
	<brief_title>Efficacy Safety Intracoronary Ad5FGF-4 Patients With Stable Angina ( AGENT-3 )</brief_title>
	<detailed_description />
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Aged 3075 year , male female , coronary artery disease Patients 50 year age agree undergo sigmoidoscopy , unless undergone exam colonoscopy within precede 36 month negative finding CCS angina Class 2 4 Stable angina = &gt; 4 week despite antianginal drug treatment , able exercise least 3 minute 10 minute first qualify baseline ETT 12 minute last qualifying baseline ETT use modify Balke exercise protocol LVEF = &gt; 30 % echocardiography , LV angiogram , MUGA scan undertaken within precede 12 month Classic angina angina equivalent associate = &gt; 1mm ST segment depression ( horizontal sloping ) least first qualify ETT . The variability exercise duration ( time grade 3/4 angina angina equivalent ) vary &gt; 20 % 2 consecutive test Single , double , triple vessel coronary artery disease . Patients 3 vessel disease least 1 proximal major vessel graft &lt; 70 % stenosis Patients require immediate PTCA CABG surgery Provided write informed consent Unstable angina CCS Class 1 angina Patients ECG evidence exercise induce myocardial ischemia difficult detect Intercurrent illness may interfere ability perform ETT Untreated lifethreatening ventricular arrhythmia Left main coronary artery stenosis = &gt; 70 % , unless bypass patent graft Coronary artery bypass surgery within past 6 month , unless graft close In situ arterial CABG RIMA LIMA , unless 100 % occlude Myocardial infarction within last 8 week CHF ( NYHA class IV ) despite treatment Angioplasty within previous 6 month Prior transmyocardial laser revascularization Enhanced external counterpulsation ( EECP ) within 12 week prior study entry Coronary ostial stenosis precludes adequate catheter engagement target vessel Coronary artery venous communication bypass coronary capillary bed Heparin associate thrombocytopenia ( HIT ) Moderate severe nonproliferative proliferative retinopathy cause ( ETDRS Score &gt; 35 ) , clinically significant macular edema , previous panretinal photocoagulation therapy History malignant neoplasm ( except superficial basal cell skin carcinoma ) within past 10 year Malignant tumor abnormal cancer screen test suspicious cancer , patient screen exams indicate possible occult malignancy , unless malignancy rule Family history colon cancer firstdegree relative , unless patient undergone colonoscopy within past 12 month negative finding Elevated PSA level ( unless prostate cancer exclude ) HIV positive Hepatic disease positive hepatitis B C , whose SGPT &gt; 2 time upper limit normal range , whose serum bilirubin &gt; 2 mg/dL . Proteinuria = &gt; 2+ unless renal parameter within normal limit . Creatinine clearance &lt; 45 ml/min Platelet count le 130 x 10 ( 3 ) /microL WBC count le 3.0 x 10 ( 3 ) /microL Patients know immunosuppressed and/or receive chronic immunosuppressive therapy Female patient childbearing potential . Male patient agree use birth control ( condom ) period 8 week follow study product administration Investigational drug therapy within 30 day treatment Patients receive gene therapy product angiogenic growth factor protein product Underlying disease ( ) CAD result life expectancy le 1 year Any clinical abnormality social circumstance put successful completion trial doubt</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>angina</keyword>
	<keyword>FGF-4</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>adenovector</keyword>
	<keyword>growth factor</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>revascularization</keyword>
</DOC>